Lancet Gastroenterology & Hepatology

Article	Citations
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	1590
Research in Brief	557
EASL Congress 2024	515
GORD: pain, PPIs, and preciseness	454
Research in Brief	447
Viral hepatitis: time for action	447
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30	421
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy	337
Immune checkpoint inhibitors in colorectal cancer: dream and reality	336
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	304
Treatment withdrawal in Crohn's disease: slowly becoming clearer	282
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	264
Lucky: Learning to Live Again	244
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	233
Trends in alcohol-specific deaths in the UK and industry responses	222
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	220
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	220
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	218
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	214
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	208
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	203
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	194
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study	187
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	183
Global multi-stakeholder endorsement of the MAFLD definition	171

Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	168
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	166
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	165
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	161
Rare cause of dysphagia in a young woman	154
Water and sanitation for all	154
ACG 2024	145
Long-term VEDOKIDS results: implications for practice and research	137
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?	136
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada	135
Availability of point-of-care HBV tests in resource-limited settings	132
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	131
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply	129
Management of portal vein thrombosis in cirrhosis	127
The potential of ctDNA in locoregional therapies for colorectal cancer	126
Idiopathic gastroparesis consensus misses the patient's voice	125
Local and systemic therapy in liver cancer: the quest for synergy	124
All roads lead to the gut–brain microbiome network	123
Research in Brief	121
Uptick of food allergies in recent years—real or epiphenomenon?	116
Has the time come for a systematic top-down approach in Crohn's disease?	113
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply	110
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study	108
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47	108
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)	105
Resmetirom for NASH: balancing promise and prudence	104
Addressing the rise of early-onset colorectal cancer	103
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	101
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis	100
Sex and gender in inflammatory bowel disease outcomes and research	100
Bringing organ preservation closer for selected patients with rectal cancer	100
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	98
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study	98
Hypovolaemic phlebotomy for hepatic resection	97
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	97
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations	94
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist	92
Managing inflammatory bowel disease: what to do when the best is unaffordable?	89
Lifting the minority tax in gastroenterology and hepatology	87
Research in Brief	85
The Year My Life Went Down the Toilet	84
Britta Siegmund: answering the big questions in IBD	83
Dangerous Medicine	80
Management of malignant bowel obstruction – Authors' reply	80
An unusual complication after a variceal glue injection	80
Research in Brief	80
A women-focused matrix mentorship programme in gastroenterology	79
The growth of faecal microbiota transplantation in the UK: time for a registry?	78
Another arrow in the NASH quiver?	77
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B	74

Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de	73
Practicalities accessing precision medicine in biliary tract cancer	73
Urgent action needed to achieve viral hepatitis elimination	73
Shitbag: the story of a diagnosis	72
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions	71
18th Congress of the European Crohn's and Colitis Organisation	71
Redefining palliation in malignant gastric outlet obstruction	71
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China	69
Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial	68
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED	67
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines	65
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities	65
CEND-1: a game changer for pancreatic cancer chemotherapy?	65
Primary biliary cholangitis and the narrowing gap towards optimal disease control	65
Robotic versus laparoscopic surgery for middle and low rectal cancer	65
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial	63
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	63
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial	62
Correction to Lancet Gastroenterol Hepatol 2021; 6: 781	60
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study	60
Research in Brief	58
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny	58
Compensation advised for UK victims of contaminated blood scandal	57
The world is failing on hunger	57
COP27 Climate Change Conference: urgent action needed for Africa and the world	56
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma	55
Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis	55
Research in brief	55
Bowel cancer prevention: are we missing an opportunity?	54
Management of portal vein thrombosis in cirrhosis – Authors' reply	54
Combining systemic and local therapies for hepatocellular carcinoma	53
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis	53
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18	53
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines	53
Primary intestinal lymphangiectasia	53
The problem of antimicrobial resistance in chronic liver disease	52
Lessons learned from the BOSS trial	52
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework	52
Alcohol and health: time for Europe to sober up	51
Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations	51
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease	51
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial	50
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study	49
Increasing burden of colorectal cancer in China	48
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review	48
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	48
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership	48
The intestinal barrier: a pivotal role in health, inflammation, and cancer	47
DEI in gastroenterology and hepatology	47
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	47
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease	46
Research in Brief	46
The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity	46
Watch and wait for rectal cancer: towards data-informed surveillance	45
The costs of inadequate toilet coverage in the Philippines	45
Gastroenterology training in Africa: an assessment of curriculum and perception	45
Diet or optimised medical therapy for people with irritable bowel syndrome	45
Does filgotinib work for Crohn's disease?	45
Correction to Lancet Gastroenterol Hepatol 2025; 10: 715–25	44
Lessons and open questions in borderline resectable pancreatic cancer	44
Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials	44
Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness	44
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus	44
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families	42
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	42
Combination locoregional and systemic therapies in hepatocellular carcinoma	42
Peroral endoscopic myotomy versus pneumatic dilation for achalasia	41
Spleen stiffness in portal hypertension algorithms: the next advance	41
Standardising early liver transplantation for severe alcohol-related hepatitis	41
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics	40
World Hepatitis Day 2025: elimination at a critical juncture	40
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial	40
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis	40
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease	40
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised contro	39
A coordinated multipronged attack: integrated care is the future for gastroenterology	39
Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial	39
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	39
The International Liver Congress 2022	39
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD	39

Research in Brief	39
Inequities in alcohol-related harm in the Philippines	39
Accelerating point-of-care HCV viral load testing	38
Research in Brief	38
Oncological safety of laparoscopic surgery for low rectal cancer	36
Inclusion of patients with isolated ulcerative proctitis in clinical trials	36
More is not always better for novel hepatitis B therapies	36
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions	35
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	35
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	35
An open letter to Gavi: hepatitis B birth dose vaccine can't wait	34
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial	33
Endoscopic interventions for stricturing Crohn's disease	32
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from	32
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomise	32
Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?	31
Time for a treat all approach for hepatitis B	31
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy	30
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better	30
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	30
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study	30
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	30
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	29
Challenging stigma around alcohol misuse	29
Launch of the International Living Donor Liver Transplantation Outcomes Registry	29
Vedolizumab in paediatric IBD: a huge step forward but not there yet	28
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply	28
Séverine Vermeire: advancing patient-centred research in IBD	28
17th Congress of ECCO	28
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	28
Research in Brief	28
Chronic Boom	27
Robotic pancreatoduodenectomy: preparing for the future	27
The Liver Meeting 2023	27
Lessons from a trial of colesevelam for bile acid diarrhoea	27
No accident: the UK infected blood scandal	27
Cultural competence in the delivery of nutrition and symptom care in irritable bowel syndrome	26
Tackling obesity: drugs are only part of the solution	26
Haematopoietic stem-cell transplantation in Crohn's disease	26
Psychological therapies in inflammatory bowel disease	25
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	25
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	25
The urgent need to end hepatitis B stigma and discrimination	25
Local ablation in pancreatic cancer: some answers and more questions	25
Retina and liver fibrosis screening for patients with type 2 diabetes	24
A new chapter in the campaign to eliminate viral hepatitis?	24
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	23
Gastric examination by guided capsule endoscopy: a new era	22
A call for advocacy and patient voice to eliminate hepatitis B virus infection	22
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	22
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	22
Comparison of trends in early-onset colorectal cancer in North America and Europe	22
Refining the faecal incontinence core outcome set – Authors' reply	22
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	22
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	21
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	21
Oral faecal microbiota transplantation in ulcerative colitis	20
Terlipressin for hepatorenal syndrome: opportunities and challenges	20
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	20
Research in Brief	19
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial	19
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	19
Financing viral hepatitis: catalysing action for impact	19
Are all post-ESWL pancreatitis events clinically significant?	19
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	19
Research in Brief	19
Diet or optimised medical therapy for people with irritable bowel syndrome	19
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	19
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply	18
NAFLD prevalence and severity in overweight and obese populations	18
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	18
Variceal embolisation plus TIPS for variceal bleeding	18
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes	18
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis	17
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	17
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	17
Non-coeliac gluten sensitivity: from Salerno to Rome	17
Intraoperative fluorescence angiography with indocyanine green to prevent anastomotic leak in rectal cancer surgery (IntAct): an unblinded randomised controlled trial	17
Septic arthritis: a presentation of Crohn's disease	17
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel	16
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	16
An important step towards the long-term treatment of eosinophilic oesophagitis	16
Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial	16
Uncouplers of mitochondrial oxidation in non-alcoholic fatty liver disease	15
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial	15
An Indigenous First Nations perspective on liver health	15
Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions	15
Research in Brief	15
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis	15
A path to global cirrhosis health equity	15
ACG 2021	14
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial – Authors' reply	14
Targeting type 2 immune responses to treat eosinophilic gastritis	14
Weighing the benefits of screening for early-onset colorectal cancer	13
Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study	13